Cullinan Therapeutics, Inc. Common Stock

CGEMNASDAQ • USD
9.96 USD
↘ 0.32 (3.11%)🟢LIVE (AS OF 11:27 AM EST)
🟢Market: OPEN

Cullinan Therapeutics, Inc. Common Stock (CGEM) is currently trading at $9.96. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 13, 2026.

Open?$10.11
High?$10.40
Low?$9.96
Prev. Close?$10.28
Volume?173.4K
Avg. Volume?889.4K
VWAP?$10.09
Rel. Volume?0.19x
Bid / Ask
Bid?$9.99 × 100
Ask?$10.44 × 100
Spread?$0.45
Midpoint?$10.22
Valuation & Ratios
Market Cap?667.4M
Shares Out?64.9M
Float?53.5M
Float %?83.2%
P/E Ratio?N/A
P/B Ratio?2.37
EPS?-$2.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Employees
109
Market Cap
667.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-01-08
Address
ONE MAIN STREET
CAMBRIDGE, MA 02142
Phone: 617-410-4650
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
99
Momentum?
50
Short Sent.?
48
Piotroski F-Score?0/9Weak
Altman Z-Score?5.21Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?14.81%High
Short Interest?7.9M
Days to Cover?13.3
Free Float53.5M
Avg Daily Volume594.7K
Settlement Date2026-10-30
Financial Health
Current Ratio?7.43Strong
Quick Ratio?7.43Strong
Cash Ratio?2.20Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
67
2.37CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-62.6%WEAK▾
ROA?
S&P
3
-54.6%WEAK▾
Cash Flow & Enterprise
FCF?$-165466000
Enterprise Value?$579.1M
Fundamentals ratios updated end of day